General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Chronic Immune Thrombocytopenia
Last updated May 9, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma (including relapsed)
Last updated May 9, 2022
Opsynvi (macitentan and tadalafil)
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Pulmonary Arterial Hypertension
Last updated May 9, 2022
Status:
Negotiations were not pursued
Manufacturer:
LEO Pharma Inc.
Indication:
Atopic dermatitis
Last updated May 3, 2022
Status:
Negotiations were not pursued
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Atherothrombotic Events in Coronary Artery Disease
Last updated May 3, 2022
Vyxeos (daunorubicin and cytarabine)
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) or newly diagnosed therapy-related acute myeloid leukaemia (t-AML) , in adults
Last updated April 27, 2022
Status:
Concluded with an LOI
Manufacturer:
HLS Therapeutics Inc.
Indication:
Ischemic events in statin-treated patients
Last updated April 25, 2022
Inqovi (decitabine-cedazuridine)
Status:
Concluded without agreement
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients
Last updated April 22, 2022
Kynmobi (apomorphine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Sunovion Pharmaceuticals Canada Inc.
Indication:
Parkinson's disease
Last updated April 4, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Tandem Diabetes Care Canada, Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated March 29, 2022